BerandaREPCF • OTCMKTS
add
0913693 B C Ord Shs
Tutup sebelumnya
$0,0020
Kapitalisasi pasar
735,78 rb CAD
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 143,51 rb | -33,15% |
Laba bersih | -8,22 jt | -3.164,08% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -143,37 rb | -13,71% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 10,47 rb | -37,07% |
Total aset | 22,53 rb | -88,88% |
Total liabilitas | 1,18 jt | -76,43% |
Total ekuitas | -1,15 jt | — |
Saham yang beredar | 73,58 jt | — |
Harga terhadap nilai buku | -0,10 | — |
Tingkat pengembalian aset | -423,02% | — |
Tingkat pengembalian modal | 17,40% | — |
Arus Kas
Perubahan kas bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -8,22 jt | -3.164,08% |
Kas dari operasi | -151,33 rb | 5,49% |
Kas dari investasi | — | — |
Kas dari pembiayaan | 159,99 rb | 59,42% |
Perubahan kas bersih | 8,66 rb | 120,38% |
Arus kas bebas | -733,81 rb | -1.378,70% |
Tentang
RepliCel Life Sciences is a Canadian regenerative medicine company based in Vancouver, British Columbia. The company focuses on development of cell therapies using a patient's own cells. The company has treatment development activities targeting chronic tendon injuries which have failed to heal properly, and hair restoration. The company's expertise lies in isolation and exploitation of different cell populations found in the human hair follicle.
The company's business model is focused on establishing proof-of-concept for treatments leading to acquisition by a larger company. An alternative business model has been reported which does not involve acquisition but rather partnership where technologies and methods are licensed to a partner which will commercialize them. Wikipedia
Didirikan
1967
Kantor pusat
Situs
Karyawan
1
